THE USE OF DANAZOL IN THE TREATMENT OF HEMOPHILIA AND CHRISTMAS DISEASE

达那唑在治疗血友病和圣诞病中的用途

• 批准号: 4692040
• 负责人: H R GRALNICK
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/4692040
• 关键词: coagulation factor VIII; congenital blood disorder; hemophilia As; hemophilia B; human therapy evaluation; human tissue; interview; testosterone

Danazol, a synthetic testosterone derivative, is being administered to patients with congenital coagulation factor deficiencies to evaluate its effect on the levels of the deficient coagulation factor and its possible clinical efficacy. Danazol had been shown to be effective in raising the factor VIII level in patients with mild and moderate hemophilia A. The response in the patients with severe hemophilia A is variable. We are presently involved in a double-blind study of the effects of Danazol in hemophilia A.

达那唑，一种合成的睾酮衍生物，正在被用于 先天性凝血因子缺乏症患者，以评估其 对缺乏凝血因子水平的影响及其可能的 临床疗效 达那唑已被证明是有效的提高 轻、中度血友病A患者凝血因子VIII水平的研究 的 在重度血友病A患者中的反应是可变的。 我们 目前参与了一项双盲研究达那唑的影响， 血友病A